US Senate panel clears patent reforms as govt seeks to cut review times
This article was originally published in Clinica
The latest US patent reform bill, called the Patent Reform Act of 2011, has been cleared by the Senate Judiciary Committee in a unanimous vote. The bill now has to be cleared by the full Senate and House. If signed into law, it would result in the first significant changes to the nation's patent system in nearly 60 years.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.